Market Performance - The pharmaceutical commercial sector increased by 0.97% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Key stocks in the pharmaceutical commercial sector showed significant gains, with Yinghe Pharmaceutical rising by 10.02% to a closing price of 22.72, and Jiashitang also increasing by 10.00% to 17.38 [1] - Other notable performers included Saili Medical and Renmin Tongtai, both showing increases of 10.00% and 2.64% respectively [1] Trading Volume and Value - Yinghe Pharmaceutical had a trading volume of 636,200 shares, resulting in a transaction value of approximately 1.396 billion yuan [1] - Jiashitang and Saili Medical also reported substantial trading volumes of 119,600 and 74,200 shares, with transaction values of around 208 million yuan and 185 million yuan respectively [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 188 million yuan from institutional investors and 252 million yuan from speculative funds, while retail investors saw a net inflow of 439 million yuan [2] - The capital flow data indicates varying investor sentiment, with retail investors showing a positive trend in the sector [2] Stock-Specific Capital Flow - Luyuan Pharmaceutical had a net inflow from retail investors of approximately 1.02 billion yuan, despite a net outflow from institutional and speculative investors [3] - Jiashitang and Saili Medical also experienced mixed capital flows, with Jiashitang seeing a net inflow of 84.96 million yuan from institutional investors [3]

据交易所数据显示， 塞力医疗连续两个交易日涨停，晋级2连板。该股今日于9时25分封涨停，成交额 1.36亿元，换手率2.60%。金融界App AI线索挖掘：近期 脑机接口概念板块延续涨势，相关领域被推动 成为新的经济增长点，同时国际头部企业宣布2026年将对脑机接口设备进行大规模生产，市场对该领域 的关注度持续提升。塞力医疗作为脑机接口概念相关个股，受板块整体热度影响。 风险提示：连板股 波动剧烈，注意追高风险，理性投资！（注：以上由AI基于交易所等公开数据生成，内容不构成投资 建议。） ...

人民财讯1月6日电，脑机接口概念继续大涨，三博脑科（301293）、美好医疗（301363）、创新医疗 （002173）、普利特（002324）、塞力医疗（603716）、岩山科技（002195）、盈趣科技（002925）等 均2连板。 ...

| | | 塞力斯医疗科技集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 12 月 31 日，累计已有 23,182 万元"塞力 转债"转为公司普通股，累计转股股数为 19,288,938 股，占"塞力转债"转股 前公司总股本的比例为 9.4084%。 一、塞力转债发行上市概况 （一）可转换公司债券发行情况 经中国证券监督管理委员会（证监许可【2020】1033号）核准，公司于2020 年8月21日公开发行了543.31万张可转换公司债券，每张面值100元，发行总额 54,331万元，期限6年。本次发行的可转换公司债券的票面利率为：第一年0.50%， 第二年0.80%，第三年1.00%，第四年1.50%，第五年2.50%，第六年3.00%。 （二）可转换公司债券上市情况 经上海证券交易所自律监管决定书【2020】306号文同意，公司发行总额为 54,331万元的可转换公司债券于2020年9月15日起在上海证券交易所挂牌交易， 债券 ...

Market Performance - The pharmaceutical commercial sector increased by 1.77% compared to the previous trading day, with Jia Shitang leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Individual Stock Performance - Jia Shitang (002462) closed at 15.80, up 10.03% with a trading volume of 224,800 shares [1] - Saily Medical (603716) closed at 22.61, up 10.02% with a trading volume of 133,500 shares [1] - Baiyang Pharmaceutical (301015) closed at 25.23, up 6.91% with a trading volume of 83,200 shares [1] - Other notable performers include Dajia Weikang (301126) up 6.51%, and Run Da Medical (603108) up 5.82% [1] Capital Flow Analysis - The pharmaceutical commercial sector saw a net inflow of 231 million yuan from institutional investors, while retail investors contributed a net inflow of 71.88 million yuan [2] - However, there was a net outflow of 303 million yuan from speculative funds [2] Detailed Capital Flow for Key Stocks - Saily Medical (603716) had a net inflow of 1.59 billion yuan from institutional investors, but a net outflow of 71.84 million yuan from speculative funds [3] - Jia Shitang (002462) experienced a net inflow of 86.98 million yuan from institutional investors, with a net outflow of 45.96 million yuan from speculative funds [3] - Hua Ren Health (301408) had a net inflow of 45.75 million yuan from institutional investors, but a significant net outflow of 65.32 million yuan from retail investors [3]

Group 1 - The cell immunotherapy concept increased by 4.73%, ranking 7th among concept sectors, with 56 stocks rising, including Guanhao Biological reaching a 20% limit up [1] - Notable gainers in the sector include International Medicine, Saily Medical, and Zhaoyan New Drug, all hitting the limit up, while stocks like Saifutian and *ST Biology experienced declines [1][2] - The cell immunotherapy sector saw a net inflow of 1.058 billion yuan, with 38 stocks receiving net inflows, and Zhaoyan New Drug leading with a net inflow of 232 million yuan [2][3] Group 2 - The top stocks by net inflow ratio include Saily Medical at 57.96%, International Medicine at 41.60%, and Zhaoyan New Drug at 22.45% [3] - The trading performance of key stocks shows Zhaoyan New Drug and Saily Medical both achieving over 10% gains, while Guanhao Biological reached a 20% increase [3][4] - Other notable performers include Bibeite and Yuekang Pharmaceutical, with increases of 11.84% and 10.13% respectively [1][5]

一、行情表现 1月5日，脑机接口板块开盘大涨。三博脑科（20CM）、岩山科技、创新医疗、南京熊猫等集体一字板，塞力医疗、盈趣科技、翔宇医疗（20CM）、荣泰 健康、国际医学、爱朋医疗（20CM）、熵基科技（20CM）、麦澜德（20CM）、诚益通（20CM）、伟思医疗（20CM）、迈普医学（20CM）等集体涨 停。 | 脑科学 +12.41% | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 理由 | | 马斯克旗下脑机接口公司2026年将启动脑机接口设备"大规模生产" | | | | | | 股票名称 | 最新价 = | 涨跌幅 = | 涨停时间 = | 换手率 = | 流通市值 ◆ | 解读 | | 三博脑科 | 70.78 | +20.01% | 09:25:00 | 6.18% | 113.92 乙 | 公司是以神经专科为特色的医疗服务集 | | 301293.SZ | | | | | | 院,其中神经专科医院4家,综合性医院 | | 美好医疗 | | | | | 107.71亿 | 公司正与下游脑机接口客户开展产品合 批量出货的商业 ...

SPD概念板块领跌，下跌1.02%，其中合富中国下跌5.04%，英特集团下跌2.8%，塞力医疗下跌1.15%。 （AI生成） ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.0% on December 30, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3965.12, also down by 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Yingte Group (000411) with a closing price of 13.23, up by 9.98% and a trading volume of 419,800 shares [1] - Yao Yigou (300937) at 35.65, up by 7.64% with 125,700 shares traded [1] - HeFu China (603122) at 26.00, up by 6.17% with a trading volume of 985,200 shares [1] - Conversely, Saily Medical (603716) saw a decline of 3.19% to a closing price of 20.95, with a trading volume of 123,200 shares [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 258 million yuan from institutional investors, while retail investors contributed a net inflow of 54.61 million yuan [2] - Notable capital flows included: - HeFu China (603122) with a net inflow of 286 million yuan from institutional investors [3] - Yingte Group (000411) with a net inflow of 134 million yuan from institutional investors [3] - Yao Yigou (300937) with a net inflow of 16.36 million yuan from institutional investors [3]

Core Viewpoint - The company, Selys Medical Technology Group Co., Ltd., is undergoing changes in its business scope and governance structure, with a focus on expanding into new product categories and preparing for a shareholder meeting to approve these changes [2][4][6]. Group 1: Stock Performance - As of December 26, 2025, Selys Medical's stock closed at 21.48 yuan, down 4.06% from the previous week's 22.39 yuan [1]. - The stock reached a high of 22.5 yuan and a low of 21.16 yuan on December 25, 2025 [1]. - The company's current total market capitalization is 4.515 billion yuan, ranking 24th out of 32 in the pharmaceutical commercial sector and 3628th out of 5178 in the A-share market [1]. Group 2: Corporate Announcements - The fifth board of directors held its 24th meeting on December 22, 2025, where it approved two key resolutions: one to expand the company's business scope and another to convene the first extraordinary general meeting of shareholders in 2026 [2][4]. - The company plans to hold the first extraordinary general meeting of shareholders on January 7, 2026, with both on-site and online voting options available [3][6]. - The proposed expansion of the business scope includes health products, cosmetics, daily chemical products, personal hygiene products, special medical purpose formula foods, pre-packaged foods, health foods, and internet sales [4][6]. Group 3: Corporate Governance - The company's articles of association were revised in December 2025, establishing it as a perpetual joint-stock company with a registered capital of 210,139,246 yuan [5]. - The articles outline shareholder rights and obligations, the powers and rules of the shareholders' meeting, responsibilities of the board of directors and supervisors, and financial accounting policies [5]. - The company aims for a cash dividend priority in profit distribution, with a commitment to distribute no less than 30% of the average distributable profit over the last three years [5].